Search clinical trials for: oxybutynin chloride

Total 3148 results

Watson Pharmaceuticals

Completed

Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers

Healthy Volunteers

United States
Allergan

Completed

Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial

Overactive Bladder

United States
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

The Effect of Extended-Release Oxybutynin Chloride on Vasomotor Symptoms in Healthy Post-Menopausal Women

Hot Flashes | Menopause
Alza Corporation, DE, USA

Completed

Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder

Urinary Incontinence
Janssen Korea, Ltd., Korea

Completed

An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants

Urinary Bladder, Overactive
McNeil Consumer & Specialty Pharmaceuticals, a...

Completed

An Effectiveness and Safety Study Comparing Oxybutynin Chloride Plus FLOMAX (Tamsulosin HCl) and Placebo Plus FLOMAX (Tamsulosin HCl) for the Treatment of Lower Urinary Tract Symptoms.

Urination Disorders
Watson Pharmaceuticals

Completed

Effects of Oxybutynin Topical Gel on Gastric Emptying

Healthy

United States
US Department of Veterans Affairs

Completed

Behavioral Treatment of Overactive Bladder in Men (MOTIVE)

Overactive Bladder

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer

Prostate Carcinoma

United States
US Department of Veterans Affairs

Completed

Enhancing Conservative Treatment for Urge Incontinence (COMBO)

Urinary Incontinence

United States
Mylan Pharmaceuticals Inc

Completed

Fed Study of Oxybutynin Chloride Extended-Release Tablets 10 mg and Ditropan XL® Tablets 10 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Oxybutynin Chloride Extended-Release Tablets 5 mg and Ditropan XL® Tablets 5 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Food Study of Oxybutynin Chloride Extended-Release Tablets 5 mg and Ditropan XL® Tablets 5 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Food Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg

Healthy

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Oxybutynin Chloride in Managing Hot Flashes

Hot Flashes | Breast Carcinoma | Lobular Breast Carcinoma In Situ | Ductal Breast Carcinoma In Situ | No Evidence of Disease

United States
Kessler Foundation
National Institute on Disability, Independent Living, and Rehabilitation...

Unknown

Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury (MOSET-SCI)

Spinal Cord Injuries | Urinary Bladder, Neurogenic

United States
Duramed Research

Completed

A Safety Extension Study of DR-OXY-301

Overactive Bladder

United States
Seoul National University Hospital
Il-Yang Pharm. Co., Ltd.

Not yet recruiting

A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)

Overactive Bladder

Korea, Republic of
Saint Petersburg State University, Russia

Recruiting

Efficacy and Safety of Focused Shockwave Therapy Plus Tadalafil vs Tadalafil Alone in Patient With Erectile Dysfunction

Erectile Dysfunction

Russian Federation
M.D. Anderson Cancer Center
Bayer; Prostate Cancer Foundation

Completed

Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases

Prostate Cancer

United States
Samantha Rodrigues Camargo Neves de Moura
Science Valley Research Institute

Not yet recruiting

Topical Oxybutynin for Treatment of Hyperidrosis: a Local or a Systemic Effect? (TODAY)

Hyperhidrosis | Sweat Gland Diseases | Skin Diseases | Oxybutynin | Autonomic Agents | Cholinergic Antagonists | Parasympatholytics

Brazil
Bayer

Completed

Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton

Prostate Cancer | Pharmacokinetics | Metastases

United States
Bayer

Completed

Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.

Overactive Bladder

United States
University of California, Davis

Recruiting

Oxybutynin for Post-surgical Bladder Pain and Urgency

Overactive Bladder Syndrome | Neuropathic Bladder

United States
Universidad de Valparaiso
Uro Medical Corporation

Enrolling by invitation

Effectiveness of Oral Boldo in Women With Overactive Bladder

Urinary Bladder, Overactive

Chile
Watson Pharmaceuticals

Completed

A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition

Detrusor Hyperreflexia

United States
Janssen-Cilag Ltd.,Thailand

Terminated

Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity (RONDO)

Detrusor Function, Overactive

Thailand
Alza Corporation, DE, USA

Completed

A Study to Evaluate the Safety and Efficacy of OROS® Oxybutynin Chloride for the Treatment of Urge Urinary Incontinence

Urinary Incontinence
Duramed Research

Completed

A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder

Overactive Bladder

United States, Canada
University of Colorado, Denver
Society for Pediatric Dermatology

Completed

A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults

Hyperhidrosis

United States
Orient Pharma Co., Ltd.

Completed

A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease

Sialorrhoea

United States
US Department of Veterans Affairs

Completed

Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease

Overactive Bladder | Parkinson's Disease

United States
University of Southern California
National Cancer Institute (NCI)

Active, not recruiting

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer | Prostate Carcinoma Metastatic in the Bone

United States
University Hospital, Bordeaux

Not yet recruiting

Early Oxybutinin Treatment for Boys With Posterior Urethral Valves (PRETIPUV)

Male Urogenital Diseases
Eastern Virginia Medical School
National Institutes of Health (NIH)

Completed

Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy

Diabetic; Neuropathic, Polyneuropathy (Manifestation)

United States
Watson Pharmaceuticals

Completed

Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder (MATRIX)

Quality of Life | Overactive Bladder | Urinary Incontinence

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Effects Of Detrol LA On Memory And Cognition In Elderly Population

Cognition | Memory

United States
Bayer

Completed

BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease

Breast Cancer | Bone Metastases

Belgium, United Kingdom, Norway
Stéphane Bolduc
Pfizer

Completed

Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children (FOXY)

Overactive Bladder
Federal University of São Paulo

Completed

A Study to Compare Oxybutynin to a Placebo in Women and the Effect on Plantar Hyperhidrosis

Hyperhidrosis
Astellas Pharma Inc

Completed

Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis (SONIC)

Multiple Sclerosis | Spinal Cord Diseases | Neurogenic Bladder

Australia, France, Belgium, Germany, Netherlands, Italy, Spain, United Kingdom, Hungary, Czechia, Russian Federation
Astellas Pharma Inc
Astellas Pharma Canada, Inc.

Completed

Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR) (VECTOR)

Overactive Bladder

Canada
Astellas Pharma Inc

Terminated

Assessment and Tracking of Long-term Alefacept Safety (ATLAS)

Psoriasis

United States, Canada
McMaster University
Hamilton Health Sciences Corporation

Completed

Fluids in Sepsis and Septic Shock (FISSH)

Sepsis | Septic Shock

Canada
Alza Corporation, DE, USA

Completed

A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence.

Urge Incontinence
University of Maryland, Baltimore
Food and Drug Administration (FDA)

Completed

Effect of Heat on Oxybutynin Release and Absorption From Oxybutynin Products

Heat Effect

United States
Imperial College London
Royal Brompton & Harefield NHS Foundation Trust

Completed

Nebulised Hypertonic Saline in Children and Young People With Neuromuscular Disease and Cerebral Palsy

Neuromuscular Diseases

United Kingdom
University of Jena

Completed

Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis

Cystic Fibrosis | Rhinosinusitis

Germany

Search clinical trials for: oxybutynin chloride

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations